clinical-microbiology-biotechnology-2019-tracks

2 / 13

allied
academies
Page 15
June 12-13, 2019 | Edinburgh, Scotland
8th European Clinical Microbiology and Immunology Congress
&
3rd World congress on Biotechnology
Joint Event
Microbiology: Current Research | Volume: 3 | ISSN: 2591-8036
Antibodies with functionality as a new generation of translational tools designed to
be pro-grammed via translational resources to predict and to prevent demyelination
Sergey Suchkov1, 2, 3, Noel Rose4, Aleks Gabibov5 and Harry Schroeder6
1 I M Sechenov First Moscow State Medical University, Russia
2 A I Evdokimov Moscow State Medical & Dental University, Russia
3 European Association for Prediction, Prevention and Personalized Medicine, Belgium
4 Johns Hopkins Medical Institutions, USA
5 Institute for Bioorganic Chemistry, Russia
6 The University of Alabama at Birmingham, USA
A bs against myelin basic protein/MBP present with the
proteolytic-activity (Ab-proteases with functionality)
of higher value to observe demyelination to show the
evolution of multiple sclerosis (MS). Anti-MBP auto-Abs
from MS patients and mice with EAE exhibited particular
proteolytic cleavage of MBP which, in turn, markedly vary
between: 1. MS patients and healthy controls; 2. Different
clinical MS courses; 3. EDSS scales of demyelination to
correspond with the disability of MS patients to predict
the transformation prior to the changes of clinical course.
Ab-mediated proteolysis of MBP was shown to be
sequence-specific while exhibiting 5 sites of preferential
proteolysis to be located within the immunodominant
regions of MBP and to fall inside into 5 sequences fixed.
Some of the latter (with the highest encephalitogenic
properties) were evident to act as a specific inducer of EAE
and to be attacked by the MBP-targeted Ab-proteases in
MS patients with the most severe (pro-gradient) clinical
courses. The other ones whilst being less immunogenic
happened to be EAE inducers very rare but were shown to
be attacked by Ab-proteases in MS patients with moderate
(remission-type) clinical courses.
The activity of Ab-proteases was initially registered at the
subclinical stages 1-2 years prior to the clinical illness.
About 24 percent of the direct MS-related relatives were
sero-positive for low active Ab-proteases from which 22
percent of the seropositive relatives establishedwere being
monitored for 2 years while demonstrating a stable growth
of Ab-associated proteolytic activity. Moreover, some of
the low-active Ab-proteases in persons at MS-related risks
(at subclinical stages of MS) and primary clinical and MRT
manifestations observed were coincided with the activity
to have its mid-level reached. Registration in the evolution
of highly immunogenic Ab-proteases would illustrate
either risks of transformation of subclinical stages into
clinical ones, or risks of exacerbations to develop.
The activity of Ab-proteases in joining with particular
sequence would confirm an increase subclinical and
predictive (translational) value of the tools as applicable
for personalized monitoring protocols. Ab-proteases can
be programmed and re-programmed to suit the needs
of the body metabolism or could be designed for the
development of principally new catalysts with no natural
counterparts. Future studies on targeted Ab-mediated
proteolysis could yield a translational tool for predicting
demyelination and thus the disability of the MS patients.
Speaker Biography
Sergey Suchkov graduated from Astrakhan State Medical University
and awarded with MD, then in 1985 maintained his PhD at the I
M Sechenov Moscow Medical Academy and in 2001, maintained
his doctorship degree at the Nat Inst of Immunology, Russia. From
1987 through 1989, he was a senior researcher at Koltzov Inst of
Developmental Biology. From 1989 through 1995, he was a head of
the lab of clinical immunology, Helmholtz Eye Research Institute in
Moscow. From 1995 through 2004, as a chair of the dept for clinical
immunology, Moscow Clinical Research Institute (MONIKI). He has
been trained at NIH; Wills Eye Hospital, PA, USA; Univ of Florida in
Gainesville; UCSF, S-F, CA, USA; Johns Hopkins University, Baltimore,
MD, USA. He was an executive secretary-in-chief of the editorial board,
biomedical science, an international journal published jointly by the
USSR Academy of Sciences and the Royal Society of Chemistry, UK. At
present, he is a chair, dept for personalized and translational medicine,
I M Sechenov First Moscow State Medical University. He is a member of
the: New York Academy of Sciences, USA; American Chemical Society
(ACS), USA; American Heart Association (AHA), USA; EPMA (European
Association for Predictive, Preventive and Personalized Medicine),
Brussels, EU; ARVO (American Association for Research in Vision and
Ophthalmology); ISER (International Society for Eye Research) and PMC
(Personalized Medicine Coalition), Washington, USA.
e:
Sergey Suchkov et al., Microbiol Curr Res, Volume 3
ISSN: 2591-8036